the role of dll3-directed agents in treating sclc
Published 8 months ago • 357 plays • Length 3:40Download video MP4
Download video MP3
Similar videos
-
2:24
the dll3-targeting bite, tarlatamab, for the treatment of sclc
-
4:32
behind the study: dll3, asc1, ttf-1 & ki-67 in precision medicine for sclc | oncotarget
-
0:38
advancing targeted therapies for sclc
-
1:15
dll3, a new biomarker for neuroendocrine tumors of the lung
-
1:01
bi 764532: a novel t-cell engager for patients with dll3 sclc and nec
-
7:14
safety and efficacy of single agent rovalpituzumab tesirine in small cell lung cancer (sclc)
-
2:13
trinity: rova-t for relapsed sclc
-
1:02
dr. david p carbone on dll3 in small-cell lung cancer
-
5:19
dll3-targeted and chemo-sensitive therapy
-
1:41
iasc wclc 2021: cx-2029 and amg 757 for lung cancer
-
4:43
first in-human trials of rovalpituzumab for sclc
-
1:51
dr. bauer on rovalpituzumab tesirine in sclc
-
3:22
evaluating tarlatamab in recurrent small cell lung cancer treatment
-
1:28
clinical trial: tarlatamab for small cell lung cancer (nct04885998)
-
1:56
tarlatamab in sclc
-
0:16
label-free live cell imaging: activated t-cell killing cancer cell
-
0:57
3d animation - how we do it (arcreative 3d animation)
-
7:50
charles m. rudin, maria catherine pietanza, todd michael bauer, et. al.